Stockscreener 앱 받기
3.39
2.42%
0.08
시장 영업 전:
3.37
-0.02
-0.59%
전일 마감가:
$3.31
열려 있는:
$3.39
하루 거래량:
1.66M
Relative Volume:
0.42
시가총액:
$1.03B
수익:
$75.13M
순이익/손실:
$-146.41M
주가수익비율:
-6.9127
EPS:
-0.4904
순현금흐름:
$-174.43M
1주 성능:
-3.69%
1개월 성능:
+6.27%
6개월 성능:
-27.10%
1년 성능:
+33.99%
1일 변동 폭
$3.36
$3.525
1주일 범위
$3.26
$3.59
52주 변동 폭
$1.8906
$6.515
앱셀레라바이오로직스 Stock (ABCL) Company Profile
명칭
Abcellera Biologics Inc
전화
(604) 559-9005
주소
150 W 4TH AVENUE, VANCOUVER
Compare ABCL vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
3.39 | 1.03B | 75.13M | -146.41M | -174.43M | -0.4904 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
앱셀레라바이오로직스 Stock (ABCL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-07 | 재개 | Leerink Partners | Outperform |
| 2024-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-02-22 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 재개 | Piper Sandler | Overweight |
| 2023-02-28 | 개시 | Cowen | Outperform |
| 2022-12-15 | 개시 | Goldman | Buy |
| 2022-11-16 | 개시 | Truist | Buy |
| 2021-12-21 | 개시 | The Benchmark Company | Buy |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-01-05 | 개시 | Berenberg | Buy |
| 2021-01-05 | 개시 | Credit Suisse | Outperform |
| 2021-01-05 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | Stifel | Buy |
모두보기
앱셀레라바이오로직스 주식(ABCL)의 최신 뉴스
Sentiment Watch: What hedge funds are buying AbCellera Biologics IncEarnings Overview Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
What sparked AbCellera Biologics to soar over 9% after hours - MSN
AbCellera Biologics (ABCL) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr
AbCellera Biologics Inc. (ABCL) - Minichart
Aug Intraday: Is AbCellera Biologics Inc affected by consumer sentiment - baoquankhu1.vn
AbCellera Biologics Eyes Integrated Biotech Shift; ABCL635 Phase II Data Due in Q3 at Forum - MarketBeat
Is AbCellera Biologics Inc a potential multi bagger2026 Sector Moves & Smart Money Movement Tracker - baoquankhu1.vn
Bear Alert: Is AbCellera Biologics Inc part of any ETF2026 Key Lessons & AI Optimized Trading Strategy Guides - baoquankhu1.vn
AbCellera at KeyBanc Forum: Strategic Advances in Biotech By Investing.com - Investing.com Canada
New CMO Appointment Strengthens AbCellera Biologics Inc. (ABCL)’s Push Into Immunology and Beyond - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Average Rating of "Hold" from Analysts - MarketBeat
AbCellera Biologics Q1 2025 Earnings Preview - MSN
AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says - MarketBeat
AbCellera at TD Cowen Conference: Strategic Pipeline Insights By Investing.com - Investing.com Canada
DNB Asset Management AS Buys Shares of 656,208 AbCellera Biologics Inc. $ABCL - MarketBeat
Holdings Thermopylae Increases Stake in AbCellera Biologics Inc - GuruFocus
Thermopylae adds AbCellera (ABCL) shares in open-market buy - Stock Titan
AbCellera (ABCL) Is Up 18.8% After Pivoting To Clinical Stage And Filing Share Offering - simplywall.st
Thermopylae Holdings adds AbCellera (ABCL) shares in $3.27 open-market buy - Stock Titan
AbCellera (ABCL) CFO adds 42,600 shares in open-market stock purchase - Stock Titan
A Look At AbCellera Biologics (ABCL) Valuation After Narrower Losses And Pipeline Progress - simplywall.st
Decoding AbCellera Biologics Inc (ABCL): A Strategic SWOT Insigh - GuruFocus
Why AbCellera (ABCL) Is Up 11.5% After Narrowing Losses And Expanding ESOP Share Capacity – And What's Next - Yahoo Finance
AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M - Insider Monkey
Abcellera Warns Growing Generative AI Use Raises Cybersecurity, Privacy, and Operational Risks - TipRanks
AbCellera Biologics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
AbCellera Biologics (ABCL) Q4 Loss Narrows To US$0.03 EPS And Tests Bearish Narratives - simplywall.st
AbCellera (ABCL) Earnings Call: Liquidity, Risks, Catalysts - TipRanks
ABCL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AbCellera Reports Full Year 2025 Business Results - BioSpace
Why Axon Enterprise Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
What Sparked AbCellera Biologics To Soar Over 9% After Hours - Bitget
AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges - GuruFocus
AbCellera Biologics Inc. (ABCL) reports Q4 loss, tops revenue estimates - MSN
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
AbCellera Biologics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ABCL) 2026-02-24 - Seeking Alpha
AbCellera Biologics Q4 Earnings Call Highlights - MarketBeat
AbCellera Biologics Inc (NASDAQ:ABCL) Reports Narrower-Than-Expected Loss on Patent Settlement Windfall - ChartMill
AbCellera Biologics (NASDAQ:ABCL) Posts Earnings Results, Beats Estimates By $0.15 EPS - MarketBeat
Abcellera Biologics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
AbCellera (ABCL) Achieves Remarkable Revenue Growth in FY25 - GuruFocus
AbCellera Biologics Inc. SEC 10-K Report - TradingView
Abcellera Biologics earnings missed by $0.35, revenue topped estimates - Investing.com South Africa
AbCellera Biologics Q4 Earnings Report: What Investors Need to Know - Benzinga
AbCellera (NASDAQ: ABCL) 2025 results show revenue jump and strong liquidity - Stock Titan
AbCellera Biologics Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
앱셀레라바이오로직스 (ABCL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):